Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
about
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitorsEffect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and DarunavirDPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variantsGenotypic testing for human immunodeficiency virus type 1 drug resistance.Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteersEvolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapyPharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.HIV chemotherapy.Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.Lopinavir-Ritonavir: a new protease inhibitor.Optimizing indinavir regimens.Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement.Lopinavir/ritonavir (ABT-378/r).Kaletra (lopinavir/ritonavir).Managing failure to antiretroviral drugs in HIV-1-infected patients.Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant womenOutcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation service.Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialMechanism of dissociative inhibition of HIV protease and its autoprocessing from a precursor.Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.Acid suppressive therapy and the effects on protease inhibitors.Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus.Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir.Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.Electronic transduction of HIV-1 drug resistance in AIDS patients.Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.
P2860
Q24554340-A3FFDB32-D8D1-4213-B6EF-A6EC4719C939Q27651021-AC98A9CA-6D7F-4538-AEBC-8F1C4636DFA4Q28361560-E5A6F842-58C6-421B-A0CB-36EBDB8D37FCQ33906239-AA61029B-0451-4A5F-BD24-73A800E01BE5Q33983047-4D390B36-49EC-4417-97B2-802EC37BB702Q34106209-BD450365-2B37-4828-8281-1FB10E69E47EQ34113462-708FE160-8CA2-41ED-9A03-F56675EE7995Q34223088-182237CE-565C-4CB5-A6CF-694DEB63E41FQ34251788-E0533B2D-C47A-4DA6-A8E2-B7F5B59249CBQ34394720-542220AD-D9B4-458D-910C-363C293725FEQ34443330-AD1B7738-F1A5-4050-BDBF-78A42586D5E3Q34459351-E62E47FC-FACE-4163-A3DB-2A89FD35F846Q34461427-7C06AC3B-4563-47CC-A812-409ADA7C4D97Q34521994-44911E5B-15D3-42D2-B800-3DD59518B331Q34544689-803430D5-9040-4A0E-8EE6-5018A504EC38Q34709832-38BF4B1F-1B60-409F-B919-60B030BAC4BDQ35063764-BF57B8A0-9DA8-498C-BF76-8B75B68A0D1DQ35103600-704852C9-20DD-4F26-BAA8-C21A5004E3B9Q35547832-3558FE62-0274-4DA8-94D8-458F59643804Q35549750-21E6A37D-7C4B-44F1-A8FF-386456143F9BQ35885190-3CCBFA57-1B2A-4849-A588-59937070834AQ36162047-C84680AE-80DC-4545-B19D-50F7C6512088Q36222013-78DEECB1-D5F5-4853-913B-4A063046FF23Q36640626-7BBB9520-5246-4C95-9772-C62A8F795CE8Q36723780-15FF2EA9-12DA-40C8-821A-52823CDBA2DDQ37018369-C71662FC-4BBC-4CCC-ABCC-C8DD122766F1Q37598680-D6109AFA-9B7F-4226-80CA-B56DD779DE12Q37598720-C7548E8A-C2D6-4A25-874A-922E8F8DF0E5Q37765571-D1DD8281-F6D4-43C4-B9E0-CDDDA32A9756Q38980548-3E911472-A6CF-4679-98A8-E8419C17AD6DQ39651236-CB5E0CF0-A895-4926-8FDA-FB2E59148A12Q41269323-68EE225A-E3A8-417E-84B5-EE3355E93942Q42971060-B767A2FC-08A7-42E5-9FB1-8455D8BD376CQ43822039-4862E412-D7A2-43F0-9466-52FAFE7CEF3FQ43971699-66408ED6-D6C5-43E6-8995-DB0D8DC14109Q44103468-6D134F29-51D5-4334-93AC-29C75E5F1409Q44309071-46F6333B-3E49-4C19-A2D5-06784E7A067AQ44453818-DD740041-59E5-45C4-9971-E03DAF329646Q44967678-0EF8A4F0-631B-4CA6-9F3A-B4018C92AF1BQ45117171-047B05B7-BC4E-48D4-AEEE-E26702C669CA
P2860
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Drug resistance and predicted ...... 1 protease inhibitor therapy.
@en
Drug resistance and predicted ...... 1 protease inhibitor therapy.
@nl
type
label
Drug resistance and predicted ...... 1 protease inhibitor therapy.
@en
Drug resistance and predicted ...... 1 protease inhibitor therapy.
@nl
prefLabel
Drug resistance and predicted ...... 1 protease inhibitor therapy.
@en
Drug resistance and predicted ...... 1 protease inhibitor therapy.
@nl
P2093
P356
P1476
Drug resistance and predicted ...... 1 protease inhibitor therapy.
@en
P2093
Petropoulos CJ
Schleif WA
Shivaprakash M
Ziermann R
P304
P356
10.1086/315782
P407
P577
2000-08-15T00:00:00Z